• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi-Aventis

Pharma stocks fall as Rep. Cummings launches drug pricing investigation

January 14, 2019 By Sarah Faulkner

Pills

Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Amgen, AstraZeneca plc, Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Sanofi leads $50m round for Enable Injections’ on-body drug-delivery platform

October 29, 2018 By Sarah Faulkner

Enable Injections on-body injector

Enable Injections said last week that it closed a $50 million Series B round, led by Sanofi (NYSE:SNY), to fund the development of its enFuse on-body drug-delivery system. Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round. Enable Injections has developed a drug-delivery device that’s designed to deliver doses […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Enable Injections, Sanofi-Aventis

Sanofi Ventures leads $17m round for Click Therapeutics

July 23, 2018 By Sarah Faulkner

Click Therapeutics logo

Click Therapeutics said today that it landed a $17 million round, led by Sanofi‘s (NYSE:SNY)  venture arm, to fund its platform of prescription digital therapeutics. The company’s commercial product, Clickotine, is designed to help people quit smoking. The digital smoking cessation program uses a personalized plan to help people overcome tobacco cravings, adhere to medication […]

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Technology, Wall Street Beat Tagged With: clicktherapeutics, Sanofi-Aventis

Sage Therapeutics’ chief scientist on discovering drugs and taking risks

June 29, 2018 By Sarah Faulkner

Sage Therapeutics

When Al Robichaud got his start as a medicinal chemist in 1991, he knew that discovering and developing drugs meant shouldering some level of risk. But around 2011, it became clear that the process for developing brain drugs was too costly and risky for major pharmaceutical companies to justify pursuing, as companies including Novartis (NYSE:NVS), GlaxoSmithKline (NYSE:GSK), […]

Filed Under: Discovery, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, Pfizer Inc., sagetherapeutics, Sanofi-Aventis

Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump

June 27, 2018 By Sarah Faulkner

Sensile Medical

Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Each company brings its own unique strength to […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, sensilemedical, Verily

Here’s how Sanofi separates true innovation from all the hype in digital health

May 18, 2018 By Sarah Faulkner

Sanofi logo

Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley. Sanofi (NYSE:SNY), for instance, has dove in feet first, striking deals with major tech players like Verily. But weeding out true disruptions from all the noise isn’t easy. “There’s […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, Verily

Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug

May 1, 2018 By Sarah Faulkner

Regeneron, Sanofi

Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive spot on the pharmacy benefit manager’s national formulary. The agreement, effective July 1, is designed to broaden patient access to the injectable medicine and lower out-of-pocket costs for eligible […]

Filed Under: Cardiovascular, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Express Scripts, Regeneron, Sanofi-Aventis

Sanofi misses estimates in Q1, announces $1.5B share buyback

April 27, 2018 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) shares fell -3% today after the company posted its first-quarter results, missing estimates on Wall Street and revealing plans for a $1.5 billion share buyback program. The Paris, France-based company saw sales decline -8.7% in the first three months of the fiscal year compared to 2017, landing at $9.55 billion for the quarter. Analysts […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Sanofi-Aventis

Sanofi’s high-capacity insulin pen wins FDA nod

March 27, 2018 By Sarah Faulkner

Sanofi's Toujeo pen

Sanofi (NYSE:SNY) reported today that its Toujeo Max SoloStar high-capacity insulin pen won FDA approval and will be available in the third quarter of this year. The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted. “This new high capacity pen has a […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis

Valeritas takes on multiple daily insulin injections with wearable V-Go device

March 8, 2018 By Sarah Faulkner

Valeritas V-Go device

There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type II diabetes are willing to skip insulin injections if they have to […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, Valeritas Inc.

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS